Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Top Cited Papers
- 14 June 2007
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 356 (24), 2457-2471
- https://doi.org/10.1056/nejmoa072761
Abstract
Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.Keywords
This publication has 28 references indexed in Scilit:
- Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE StudyCurrent Medical Research and Opinion, 2005
- The Clinical Significance of PPAR Gamma AgonismCurrent Molecular Medicine, 2005
- Addition of rosiglitazone to metformin is most effective in obese, insulin‐resistant patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2003
- A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2002
- A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 DiabetesDiabetes Care, 2001
- Once- and Twice-Daily Dosing With Rosiglitazone Improves Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2001
- Rosiglitazone Monotherapy Is Effective in Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2001
- Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes MellitusJAMA, 2000
- Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patientsDiabetic Medicine, 2000
- Medical significance of peroxisome proliferator-activated receptorsThe Lancet, 1999